Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1994-7-26
|
pubmed:abstractText |
Mutants and fusion products of the c-abl gene were used to define some of the molecular requirements for rapid plasmacytoma (PC) and pre-B-lymphoma induction in pristane-treated N-myc transgenic BALB/c mice. A-MuLV induced PCs in 21 of 25 mice with a mean post-pristane latency period of 46 +/- 9 days, compared to 134 +/- 25 days in controls exposed to pristane alone. delta XB, a mutant of type IV c-abl with a deletion of the SH3 domain, was equally effective in inducing PCs in 7 of 7 mice with a latency period of 49 +/- 7 days, indicating that gag sequences are not required for rapid PC induction. The delta XB delta Nar mutant that carried a large C-terminal deletion in addition showed only a negligible activity, if any, suggesting that PC acceleration requires the C-terminal domain in the same way as lymphoid transformation and in contrast to fibroblast transformation. BCR-ABL fusion constructs encoding an 185-kDa protein as in acute leukemia, or a 210-kDa protein as in chronic myelocytic leukemia (CML), did not accelerate pristane-induced PC development in the N-myc transgenic mice, in contrast to their known ability to immortalize lymphoid cells in vitro. Only one of 14 non-transgenic littermates developed a pre-B lymphoma after A-MuLV infection, and none of 10 normal littermates infected with delta XB virus developed a construct-carrying tumor. This result suggests that PC acceleration is due to co-operative interaction of the N-myc transgene and activated abl. Infection of N-myc transgenic bone marrow or spleen cells with A-MuLV in vitro led to the outgrowth of pre-B lymphomas after transplantation to pristane-treated BALB/c recipients. The lymphoma-inducing activity of A-MuLV depends on its high titer, since diluted A-MuLV or the lower-titered delta XB induced only PCs under the same conditions. The v-abl, delta XB and BCR-ABL-carrying viruses generated immortalized lymphoblastoid lines in vitro, regardless of the presence of the N-myc transgene, suggesting that lymphoid transformation is a direct function of appropriate abl sequences in contrast to PC acceleration.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
58
|
pubmed:geneSymbol |
N-myc,
c-abl,
gag,
myc,
v-abl
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
135-41
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8014009-Animals,
pubmed-meshheading:8014009-Bone Marrow,
pubmed-meshheading:8014009-Bone Marrow Cells,
pubmed-meshheading:8014009-Cell Transformation, Viral,
pubmed-meshheading:8014009-Fusion Proteins, bcr-abl,
pubmed-meshheading:8014009-Genes, abl,
pubmed-meshheading:8014009-Genes, myc,
pubmed-meshheading:8014009-Leukemia Virus, Murine,
pubmed-meshheading:8014009-Lymphoma, B-Cell,
pubmed-meshheading:8014009-Mice,
pubmed-meshheading:8014009-Mice, Inbred BALB C,
pubmed-meshheading:8014009-Mice, Inbred C57BL,
pubmed-meshheading:8014009-Mice, Transgenic,
pubmed-meshheading:8014009-Plasmacytoma,
pubmed-meshheading:8014009-Precancerous Conditions,
pubmed-meshheading:8014009-Spleen,
pubmed-meshheading:8014009-Terpenes
|
pubmed:year |
1994
|
pubmed:articleTitle |
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
|
pubmed:affiliation |
Microbiology and Tumorbiology Center (MTC), Karolinska Institute, Stockholm, Sweden.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|